A
1.58
-0.07 (-4.25%)
Previous Close | 1.65 |
Open | 1.70 |
Volume | 35,240 |
Avg. Volume (3M) | 40,546 |
Market Cap | 24,302,928 |
Price / Sales | 205.85 |
Price / Book | 3.05 |
52 Weeks Range |
Operating Margin (TTM) | -5,822.92% |
Diluted EPS (TTM) | -3.19 |
Quarterly Revenue Growth (YOY) | 75.60% |
Total Debt/Equity (MRQ) | 149.87% |
Current Ratio (MRQ) | 2.89 |
Operating Cash Flow (TTM) | -29.93 M |
Levered Free Cash Flow (TTM) | -28.82 M |
Return on Assets (TTM) | -82.76% |
Market Trend
Short Term | Medium Term | ||
Industry | Medical Devices (US) | Mixed | Bearish |
Medical Devices (Global) | Mixed | Bearish | |
Stock | Adagio Medical Holdings, Inc | - | - |
AIStockmoo Score
0.9
Analyst Consensus | 0.0 |
Insider Activity | NA |
Price Volatility | -2.0 |
Technical Moving Averages | 3.5 |
Technical Oscillators | 2.0 |
Average | 0.88 |
Adagio Medical Holdings Inc is an innovator in catheter ablation technologies for the treatment of cardiac arrhythmias. The company focuses on developing cryoablation technologies that create contiguous, transmural lesions to treat cardiac arrhythmias, including paroxysmal and persistent atrial fibrillation, atrial flutter, and ventricular tachycardia. |
|
Sector | Healthcare |
Industry | Medical Devices |
% Held by Insiders | 0.29% |
% Held by Institutions | 85.46% |
No data within this time range.
No data within this time range.
Date | Type | Details |
---|---|---|
08 Sep 2025 | Announcement | Adagio Medical Expands Chief Business Officer Deborah Kaster’s Role to Include Chief Financial Officer Responsibilities |
13 Aug 2025 | Announcement | Adagio Medical Reports Second Quarter 2025 Results |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
Realized Profit | - |
Unrealized Profit | - |
Dividend Received 2025 | - |
Total Profit | - |
Avg. Return | - |
Quantity (Buy) | - |
Avg. Price (Buy) | - |
Quantity (Sold) | - |
Avg. Price (Sold) | - |